Hot on the heels of UCB's temporary set back, Ipsen has swooped in to scoop up UCB's Lupus program. Mark Le Grenouille remarked "The epratuzumab program has the promise to be Ipsen's most promising pipeline compound. The data announced by UCB today suggest that epratuzumab is likely to be Ipsen's top revenue generating brand".
